Skip to main content

Table 1 Patients’ and disease characteristics

From: Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation

Age
 median (range), years 61 (41–88)
  ≤ 60, N (%) 86 (46)
  > 60 to ≤70, N (%) 64 (34)
  > 70 to ≤80, N (%) 27 (15)
  > 80, N (%) 9 (5)
Gender, N (%)
 female 40 (22)
 male 146 (79)
Smoking status
 never smoker 17 (6)
 previous smoker 33 (31)
 current smoker 58 (54)
 missing 108
High risk alcohol consumption
 No 49 (46)
 Yes 54 (51)
 in the past 4 (4)
 missing 79
Karnofsky Performance Status
 median (range) 90 (50–100)
  > 70, N (%) 160 (86)
  ≤ 70, N (%) 26 (14)
Oncological resection of primary tumor
 yes 56 (30)
 no 130 (70)
Induction chemotherapy
 yes 15 (8)
 no 171 (92
Concomitant systemic therapy
 no 38 (20)
 cisplatin or carboplatin 125 (67)
 cetuximab 23 (12)
Site of primary tumor, N (%)
 oral cavity 52 (28)
 oropharynx 83 (45)
 hypopharynx 27 (15)
 larynx 24 (13)
UICC stage, N (%)
 I 5 (3)
 II 11 (6)
 III 44 (24)
 IV 126 (68)
Tumor grade, N (%)
 G1 1 (1)
 G2 113 (61)
 G3 72 (39)
Hemoglobin (g/dL)
 median (IQR) 13.3 (12.0–14.4)
 missing 12
Neutrophil-to-lymphocyte ratio
 median (IQR) 3.28 (2.15–4.70)
 missing 20
Platelet-to-lymphocyte ratio
 median (IQR) 189 (136–254)
 missing 20
  1. IQR inter-quartile range, UICC Union for International Cancer Control